Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin Mesylate in Metastatic Urothelial Tract Cancer and Renal Insufficiency
NCT00365157Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2006
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in urothelial carcinoma (UC), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 21 days and Overall Response Rate at 6 months. Started Oct 2006; status: active, not recruiting.
02
Drugs
eribulin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00365157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365157.